Sign up
Pharma Capital

Amryt Pharma expands exclusive licence agreement for Lojuxta

Rory Nealon, chief operating officer at Amryt Pharma PLC (LON:AMYT), tells Proactive's Andrew Scott they've signed an agreement with Aegerion Pharmaceuticals Inc to significantly expand their exclusive licence agreement for Lojuxta into Russia and the Commonwealth of Independent States, as well as the non-EU Balkan States.

Nealon says there could be up to 450 additional patients in the countries covered by the agreement who could benefit from Lojuxta - which treats a rare life-threatening disorder that causes abnormally high levels of "bad" cholesterol.

 

View full AMYT profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.